with Dahlia Biosciences
Un Kwon is a co-founder & the CEO of Dahlia Biosciences. Dahlia is developing cell-based RNA detection tools using CRISPR-Cas9 technology. Previously, Un was the Chief Strategy Officer at Caribou Biosciences, a CRISPR-Cas9 gene editing technology platform company spun out from the laboratory of Dr. Jennifer Doudna. Prior to Caribou, Un was the VP of Corporate Development at Fluidigm, a life science tools company focused on single-cell-analysis, and a life science tools/diagnostics investment research analyst at Pacific Growth Equities. Un has a M.Sc. in Molecular and Cellular Biology from University of Toronto, B.Sc. in Biochemistry from Queen’s University, and is a Chartered Financial Analyst.